Astrazeneca stock price has attracted renewed buying interest

AstraZeneca stock price has attracted renewed buying interest following news of strategic biotech acquisitions. Analysts forecast synergy gains that could lift EPS by 6% year-over-year. President Trump has announced that pharmaceutical tariffs, including those affecting AstraZeneca products, could take effect shortly. The tariffs are expected to roll out at lower initial rates and increase over time. Russ Mould, investment director at the stockbroker AJ Bell, said: “Although there has been no suggestion that AstraZeneca is imminently going to up sticks and move its primary listing from London, there may be some nervousness this morning around the risk that the UK market might lose one of its largest constituents. AstraZeneca stock price gained traction after its CEO reaffirmed long-term growth targets. Strategic investments in rare disease treatments signal a robust expansion pipeline.